Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solrikitug PK and Safety in Healthy Japanese and Non-Japanese Participants
NCT06868082Phase 1Completed
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of solrikitug in asthma and chronic obstructive pulmonary disease (COPD) (3 cohorts). Primary endpoint: Treatment-Emergent Adverse Events at 165 days. Started Jun 2025; status: completed.
02
Drugs
solrikitug
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06868082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868082.